Top

Published in:

01-02-2011 | Preclinical study

Coexpression of atypical chemokine binders (ACBs) in breast cancer predicts better outcomes

Authors: Xiao-Hua Zeng, Zhou-Luo Ou, Ke-Da Yu, Lan-Yun Feng, Wen-Jing Yin, Jing Li, Zhen-Zhou Shen, Zhi-Ming Shao

Published in: Breast Cancer Research and Treatment | Issue 3/2011

Abstract

Some evidence suggests that atypical chemokine binders (ACBs) including DARC, D6, and CCX-CKR play an important role in inhibiting invasion and metastasis of cancer cells; however, their expression in breast cancer has not been well characterized. The purpose of this study was to determine the predictive value of ACBs for relapse-free survival and overall survival in breast cancer. The expressions of the three molecules were analyzed immunohistochemically in a total of 558 consecutive breast specimens comprising 12 normal breast tissues, 29 noninvasive (carcinoma in situ), and 517 invasive breast carcinoma and their relationships to clinicopathological features and survival were investigated in invasive breast cancer. Coexpression of ACBs in invasive breast carcinoma (55.9%) was much lower that of noninvasive breast carcinoma (93.1%) and normal breast tissue (100.0%), P = 0.0004, 0.0096, respectively. Their separate stainings in invasive cancer were significantly conversely correlated with lymph node status and tumor stage. In univariate analysis, the three proteins and their coexpression were significantly associated with higher relapse-free survival and overall survival. In multivariate analysis, each of these molecules was favorable for relapse-free survival, but not overall survival. Surprisingly, their coexpression was not only independently prognostic factor for relapse-free survival (RR = 0.182, 95% CI: 0.101–0.327, P < 0.001), but also for overall survival (RR = 0.271, 95% CI: 0.081–0.910, P = 0.035). These findings highlight that the multiple loss of ACBs may occur during the development of tumorigenesis and their coexpression in breast cancer is predictive of favorable outcomes.

Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50–56CrossRefPubMed

Ben-Baruch A (2008) Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 25(4):345–356CrossRefPubMed

Ali S, Lazennec G (2007) Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev 26(3–4):401–420CrossRefPubMed

Wang JM, Chertov O, Proost P, Li JJ, Menton P, Xu L, Sozzani S, Mantovani A, Gong W, Schirrmacher V et al (1998) Purification and identification of chemokines potentially involved in kidney-specific metastasis by a murine lymphoma variant: induction of migration and NF-kappaB activation. Int J Cancer 75(6):900–907CrossRefPubMed

Ben-Baruch A (2006) The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 25(3):357–371CrossRefPubMed

Kulbe H, Levinson NR, Balkwill F, Wilson JL (2004) The chemokine network in cancer—much more than directing cell movement. Int J Dev Biol 48(5–6):489–496CrossRefPubMed

Peiper SC, Wang ZX, Neote K, Martin AW, Showell HJ, Conklyn MJ, Ogborne K, Hadley TJ, Lu ZH, Hesselgesser J et al (1995) The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor. J Exp Med 181(4):1311–1317CrossRefPubMed

Nibbs RJ, Wylie SM, Pragnell IB, Graham GJ (1997) Cloning and characterization of a novel murine beta chemokine receptor, D6. Comparison to three other related macrophage inflammatory protein-1alpha receptors, CCR-1, CCR-3, and CCR-5. J Biol Chem 272(19):12495–12504CrossRefPubMed

Gosling J, Dairaghi DJ, Wang Y, Hanley M, Talbot D, Miao Z, Schall TJ (2000) Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK. J Immunol 164(6):2851–2856PubMed

10.

Kashiwazaki M, Tanaka T, Kanda H, Ebisuno Y, Izawa D, Fukuma N, Akimitsu N, Sekimizu K, Monden M, Miyasaka M (2003) A high endothelial venule-expressing promiscuous chemokine receptor DARC can bind inflammatory, but not lymphoid, chemokines and is dispensable for lymphocyte homing under physiological conditions. Int Immunol 15(10):1219–1227CrossRefPubMed

11.

Fra AM, Locati M, Otero K, Sironi M, Signorelli P, Massardi ML, Gobbi M, Vecchi A, Sozzani S, Mantovani A (2003) Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. J Immunol 170(5):2279–2282PubMed

12.

Locati M, Torre YM, Galliera E, Bonecchi R, Bodduluri H, Vago G, Vecchi A, Mantovani A (2005) Silent chemoattractant receptors: D6 as a decoy and scavenger receptor for inflammatory CC chemokines. Cytokine Growth Factor Rev 16(6):679–686CrossRefPubMed

13.

Graham GJ, McKimmie CS (2006) Chemokine scavenging by D6: a movable feast? Trends Immunol 27(8):381–386CrossRefPubMed

14.

Hansell CA, Simpson CV, Nibbs RJ (2006) Chemokine sequestration by atypical chemokine receptors. Biochem Soc Trans 34(Pt 6):1009–1013PubMed

15.

Haraldsen G, Rot A (2006) Coy decoy with a new ploy: interceptor controls the levels of homeostatic chemokines. Eur J Immunol 36(7):1659–1661CrossRefPubMed

16.

Comerford I, Litchfield W, Harata-Lee Y, Nibbs RJ, McColl SR (2007) Regulation of chemotactic networks by ‘atypical’ receptors. Bioessays 29(3):237–247CrossRefPubMed

17.

Horuk R, Wang ZX, Peiper SC, Hesselgesser J (1994) Identification and characterization of a promiscuous chemokine-binding protein in a human erythroleukemic cell line. J Biol Chem 269(26):17730–17733PubMed

18.

Desbaillets I, Diserens AC, Tribolet N, Hamou MF, Van Meir EG (1997) Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med 186(8):1201–1212CrossRefPubMed

19.

Tang T, Owen JD, Du J, Walker CL, Richmond A (1998) Molecular cloning and characterization of a mouse gene with homology to the Duffy-antigen receptor for chemokines. DNA Seq 9(3):129–143PubMed

20.

Lentsch AB (2002) The Duffy antigen/receptor for chemokines (DARC) and prostate cancer: a role as clear as black and white? FASEB J 16(9):1093–1095CrossRefPubMed

21.

Shen H, Schuster R, Stringer KF, Waltz SE, Lentsch AB (2006) The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J 20(1):59–64CrossRefPubMed

22.

Bandyopadhyay S, Zhan R, Chaudhuri A, Watabe M, Pai SK, Hirota S, Hosobe S, Tsukada T, Miura K, Takano Y et al (2006) Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat Med 12(8):933–938CrossRefPubMed

23.

Addison CL, Belperio JA, Burdick MD, Strieter RM (2004) Overexpression of the Duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer 4:28CrossRefPubMed

24.

Horton LW, Yu Y, Zaja-Milatovic S, Strieter RM, Richmond A (2007) Opposing roles of murine Duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth. Cancer Res 67(20):9791–9799CrossRefPubMed

25.

Nibbs RJ, Kriehuber E, Ponath PD, Parent D, Qin S, Campbell JD, Henderson A, Kerjaschki D, Maurer D, Graham GJ et al (2001) The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am J Pathol 158(3):867–877PubMed

26.

Daibata M, Matsuo Y, Machida H, Taguchi T, Ohtsuki Y, Taguchi H (2004) Differential gene-expression profiling in the leukemia cell lines derived from indolent and aggressive phases of CD56+ T-cell large granular lymphocyte leukemia. Int J Cancer 108(6):845–851CrossRefPubMed

27.

Martinez de la Torre Y, Buracchi C, Borroni EM, Dupor J, Bonecchi R, Nebuloni M, Pasqualini F, Doni A, Lauri E, Agostinis C et al (2007) Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc Natl Acad Sci USA 104(7):2319–2324CrossRefPubMed

28.

Borroni EM, Buracchi C, de la Torre YM, Galliera E, Vecchi A, Bonecchi R, Mantovani A, Locati M (2006) The chemoattractant decoy receptor D6 as a negative regulator of inflammatory responses. Biochem Soc Trans 34(Pt 6):1014–1017PubMed

29.

Nibbs RJ, Gilchrist DS, King V, Ferra A, Forrow S, Hunter KD, Graham GJ (2007) The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Investig 117(7):1884–1892CrossRefPubMed

30.

Vetrano S, Borroni EM, Sarukhan A, Savino B, Bonecchi R, Correale C, Arena V, Fantini M, Roncalli M, Malesci A et al (2009) The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6. Gut 59:197–206

31.

Wang J, Ou ZL, Hou YF, Luo JM, Shen ZZ, Ding J, Shao ZM (2006) Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene 25(54):7201–7211CrossRefPubMed

32.

Wu FY, Ou ZL, Feng LY, Luo JM, Wang LP, Shen ZZ, Shao ZM (2008) Chemokine decoy receptor d6 plays a negative role in human breast cancer. Mol Cancer Res 6(8):1276–1288CrossRefPubMed

33.

Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM (2009) Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res 15(9):2962–2970CrossRefPubMed

34.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067–9072CrossRefPubMed

35.

Hayes DF, Ethier S, Lippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 100(2):237–238CrossRefPubMed

36.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235CrossRefPubMed

37.

Yu KD, Di GH, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM (2007) Development and trends of surgical modalities for breast cancer in China: a review of 16-year data. Ann Surg Oncol 14(9):2502–2509CrossRefPubMed

38.

Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SG (2005) Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 89(2):173–178CrossRefPubMed

39.

Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29(4):577–580PubMed

40.

Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3):138–140PubMed

41.

Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, Wu J, Shen KW, Han QX, Shen ZZ et al (2009) Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 115(2):325–333CrossRefPubMed

42.

Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL et al (2004) Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 88(1):75–85CrossRefPubMed

43.

Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, Roques S, Lazennec G (2007) Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9(1):R15CrossRefPubMed

44.

Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, Chaitchik S, Keydar I, Ben-Baruch A (1999) Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 59(18):4681–4687PubMed

45.

Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, Azenshtein E, Greenberg I, Keydar I, Ben-Baruch A (2006) The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 12(15):4474–4480CrossRefPubMed

46.

Fanti P, Nazareth M, Bucelli R, Mineo M, Gibbs K, Kumin M, Grzybek K, Hoeltke J, Raiber L, Poppenberg K et al (2003) Estrogen decreases chemokine levels in murine mammary tissue: implications for the regulatory role of MIP-1 alpha and MCP-1/JE in mammary tumor formation. Endocrine 22(2):161–168CrossRefPubMed

47.

Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K (2000) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6(8):3282–3289PubMed

48.

Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N, Haruma K, Chayama K (2002) Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 102(3):220–224CrossRefPubMed

49.

Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, Zhang J (2007) CCR2 expression correlates with prostate cancer progression. J Cell Biochem 101(3):676–685CrossRefPubMed

50.

Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F, Pasquali C, Calori G, Pessi F, Sperti C et al (2003) The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 63(21):7451–7461PubMed

51.

Ferreira FO, Ribeiro FL, Batista AC, Leles CR, de Cassia Goncalves Alencar R, Silva TA (2008) Association of CCL2 with lymph node metastasis and macrophage infiltration in oral cavity and lip squamous cell carcinoma. Tumour Biol 29(2):114–121CrossRefPubMed

52.

Lebrecht A, Grimm C, Lantzsch T, Ludwig E, Hefler L, Ulbrich E, Koelbl H (2004) Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol 25(1–2):14–17CrossRefPubMed

53.

Holland JD, Kochetkova M, Akekawatchai C, Dottore M, Lopez A, McColl SR (2006) Differential functional activation of chemokine receptor CXCR4 is mediated by G proteins in breast cancer cells. Cancer Res 66(8):4117–4124CrossRefPubMed

54.

Nakata B, Fukunaga S, Noda E, Amano R, Yamada N, Hirakawa K (2008) Chemokine receptor CCR7 expression correlates with lymph node metastasis in pancreatic cancer. Oncology 74(1–2):69–75CrossRefPubMed

55.

Wang J, Seethala RR, Zhang Q, Gooding W, van Waes C, Hasegawa H, Ferris RL (2008) Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy. J Natl Cancer Inst 100(7):502–512CrossRefPubMed

56.

Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST (2001) Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 93(21):1638–1643CrossRefPubMed

57.

Bieche I, Chavey C, Andrieu C, Busson M, Vacher S, Le Corre L, Guinebretiere JM, Burlinchon S, Lidereau R, Lazennec G (2007) CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer 14(4):1039–1052CrossRefPubMed

58.

Smith KC, Bateman AC, Fussell HM, Howell WM (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31(4):167–173CrossRefPubMed

59.

Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY (2004) Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 10(21):7157–7162CrossRefPubMed

60.

Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R (2004) Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 10(20):6789–6795CrossRefPubMed

61.

Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A (2001) Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 7(2):285–289PubMed

Title: Coexpression of atypical chemokine binders (ACBs) in breast cancer predicts better outcomes
Authors: Xiao-Hua Zeng
Zhou-Luo Ou
Ke-Da Yu
Lan-Yun Feng
Wen-Jing Yin
Jing Li
Zhen-Zhou Shen
Zhi-Ming Shao
Publication date: 01-02-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0875-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Mutations and polymorphic BRCA variants transmission in breast cancer familial members

Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer

Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern

Changes in leadership of breast cancer research and treatment

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies

Breast cancer prognostic markers in the post-genomic era

Keynote webinar | Spotlight on antibody–drug conjugates in cancer